ClarVista Medical, Inc.

Company Summary

ClarVista develops the HARMONI Modular IOL System, a novel intraocular lens (IOL) used to restore vision and improve patient outcomes after cataract surgery, the highest volume outpatient procedure.

Transaction Overview

On 15 May, 2015, ClarVista Medical announced that it has secured $14 million in Series B financing co-led by Cycad Group and Windham Venture Partners alongside existing investor New Enterprise Associates.
In conjunction with the financing, Robert Balch of Cycad Group and Cynthia Yee of Windham Venture Partners will join ClarVista’s board of directors.

Significance of the Transaction

The Series B financing permit the Company to advance the clinical development of HARMONI Modular IOL capable of optimizing vision after cataract surgery. Alcon, who also participated in the financing, acquired ClarVista Medical in 2017. Although terms were not publicly disclosed this outcome represented an ultimate exit and successful transaction for investors.

Healthios Role

If you would like to learn more information about this transaction contact us below.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Private Placement

ClarVista Medical, Inc.

Has completed its $14,000,000 Equity financing by a syndicate of financial investors

The undersigned acted as exclusive advisor to ClarVista medical